Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3)

References

• Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393–1407.e1395.
   Web of Science ®Google Scholar
• Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203–209.
   PubMed Web of Science ®Google Scholar
• Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114 e113.
   PubMed Web of Science ®Google Scholar
• Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013;19(9):755–764.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541–550.
   PubMed Web of Science ®Google Scholar
• Ballou S, McMahon C, Lee HN, et al. Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. Clin Gastroenterol Hepatol. 2019;17(12):2471–2478 e2473.
   PubMed Web of Science ®Google Scholar
• Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–917.
   PubMed Web of Science ®Google Scholar
• Shah ED, Almario CV, Spiegel BM, Chey WD. Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: results of a Nationwide Population-Based Study. Am J Gastroenterol. 2020;115(2):294–301.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Parikh M, Taylor DCA. Prevalence and impact of abdominal symptoms in patients with IBS-C. Am J Gastroenterol. 2021;116:S229–S230.
   PubMedGoogle Scholar
• Taylor DCA, Abel JL, Martin C, et al. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR). J Med Econ. 2020;23(10):1072–1083.
   PubMed Web of Science ®Google Scholar
• Palsson OS, Whitehead W, Tornblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262–1273 e1263.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology. 2005;128(3):580–589.
   PubMed Web of Science ®Google Scholar
• Garrigues V, Mearin F, Badia X, et al. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther. 2007;25(3):323–332.
   PubMed Web of Science ®Google Scholar
• Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol. 2012;107(2):286–295.
   PubMed Web of Science ®Google Scholar
• Rangan V, Ballou S, Shin A, Camilleri M, Lembo A. Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. Gastroenterology. 2020;158(3):786–788 e781.
   PubMed Web of Science ®Google Scholar
• Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: a Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042–1054 e1041.
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability–a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004;20(11–12):1317–1322.
   PubMed Web of Science ®Google Scholar
• Peritore-Galve FC, Kaji I, Smith A, et al. Increased intestinal permeability and downregulation of absorptive ion transporters Nhe3, Dra, and Sglt1 contribute to diarrhea during Clostridioides difficile infection. Gut Microbes. 2023;15(1):2225841.
   PubMed Web of Science ®Google Scholar
• Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133–146.
   PubMed Web of Science ®Google Scholar
• Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196–201.
   PubMed Web of Science ®Google Scholar
• Shulman RJ, Jarrett ME, Cain KC, Broussard EK, Heitkemper MM. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol. 2014;49(11):1467–1476.
   PubMed Web of Science ®Google Scholar
• Vazquez-Roque MI, Camilleri M, Smyrk T, et al. Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):G1262–G1269.
   PubMed Web of Science ®Google Scholar
• Krystel-Whittemore M, Dileepan KN, Wood JG. Mast Cell: a Multi-Functional Master Cell. Front Immunol. 2015;6:620.
   PubMed Web of Science ®Google Scholar
• Hanning N, Edwinson AL, Ceuleers H, et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586.
   Web of Science ®Google Scholar
• Sequeira IR, Lentle RG, Kruger MC, Hurst RD. Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability. PLoS One. 2014;9(6):e99256.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Verne ML, Fields JZ, et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996–1002.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775–G785.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146(1–2):41–46.
   PubMed Web of Science ®Google Scholar
• Vivinus-Nebot M, Dainese R, Anty R, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol. 2012;107(1):75–81.
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702.
   PubMed Web of Science ®Google Scholar
• Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26–37.
   PubMed Web of Science ®Google Scholar
• Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57(7):923–929.
   PubMed Web of Science ®Google Scholar
• Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri JP. Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases. Lab Invest. 1989;60(6):847–851.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Oshima T, Huang X, Tomita T, Fukui H, Miwa H. Microinflammation in the intestinal mucosa and symptoms of irritable bowel syndrome. J Gastroenterol. 2022;57(2):62–69.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16(6):1171–1185.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17–44.
   PubMed Web of Science ®Google Scholar
• Shah SL, Janisch NH, Crowell M, Lacy BE. Patients With Irritable Bowel Syndrome Are Willing to Take Substantial Medication Risks for Symptom Relief. Clin Gastroenterol Hepatol. 2021;19(1):80–86.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Everhart KK, Weiser KT, et al. IBS patients’ willingness to take risks with medications. Am J Gastroenterol. 2012;107(6):804–809.
   PubMed Web of Science ®Google Scholar
• Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology. 2022;163(1):118–136.
   PubMed Web of Science ®Google Scholar
• ZELNORM® (tegaserod) Notice of Withdrawal from Market (2022) [press release]. Available from: https://www.myzelnorm.com/assets/pdfs/Press%20Release%20on%20Notice%20of%20Withdrawal.pdf. Accessed November, 2023.
   Google Scholar
• AGA Institute. Clinical Decision Support Tool: IBS Treatment. Gastroenterology. 2022;163(1):152.
   Google Scholar
• Cuppoletti J, Blikslager AT, Chakrabarti J, Nighot PK, Malinowska DH. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacol. 2012;12:3.
   PubMedGoogle Scholar
• King AJ, Siegel M, He Y, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10(456):eaam6474.
   PubMed Web of Science ®Google Scholar
• Ardelyx, Inc. IBSRELA^® (tenapanor). Ardelyx, Inc; 2022.
   Google Scholar
• Ardelyx, Inc. XPHOZAH^® (tenapanor). Ardelyx, Inc; 2023.
   Google Scholar
• Xue J, Thomas L, Tahmasbi M, et al. An inducible intestinal epithelial cell-specific NHE3 knockout mouse model mimicking congenital sodium diarrhea. Clin Sci (Lond). 2020;134(8):941–953.
   PubMed Web of Science ®Google Scholar
• Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. A Phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21(3):407–416.
   PubMed Web of Science ®Google Scholar
• Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: two Trials in Healthy Volunteers. Clin Drug Investig. 2018;38(4):341–351.
   PubMed Web of Science ®Google Scholar
• King AJ, Chang L, Li Q, et al. NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons. Am J Physiol Gastrointest Liver Physiol. 2024;326(5):G543–G554.
   PubMed Web of Science ®Google Scholar
• Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: a 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). Am J Gastroenterol. 2020;115(2):281–293.
   PubMed Web of Science ®Google Scholar
• Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: a 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol. 2021;116(6):1294–1303.
   PubMed Web of Science ®Google Scholar
• Lembo A, Brenner DM, Lacy BE, Zhao S, Rosenbaum DP. Analysis of patient-reported treatment satisfaction and abdominal score in patients with irritable bowel syndrome with constipation (IBS-C) treated with tenapanor. Gastroenterology. 2023;164(6):S1059.
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Friedenberg KA, Fogel RP, et al. Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study. Neurogastroenterol Motil. 2023;35(11):e14658.
   PubMed Web of Science ®Google Scholar